Clinical

Data are scarce regarding the benefits of strength training for muscular dystrophies, for which there are no cures.

Investigators say a better understanding of risk factors and categories can help personalize care for patients living with myelodysplastic syndrome (MDS).

Population-level data highlight varied risk profiles among patients with indolent systemic mastocytosis (ISM), highlighting the need for individualized treatment approaches, according to Sudipto Mukherjee, MD, PhD, MPH, a physician in the department of hematology and medical oncology at Cleveland Clinic.

More than half of US adults have a favorable view of the Affordable Care Act (ACA); smartwatches and rings that claim to measure blood sugar levels without piercing the skin could be dangerous and should be avoided; many believe artificial intelligence (AI) could be the solution to physician burnout.

For chimeric antigen receptor T-cell therapies (CAR T) approved to treat B-cell lymphoproliferative disorders and multiple myeloma, more data are needed on the effects of posttreatment myeloid neoplasms to optimize patient counseling, risk stratification, and surveillance.

Results of a phase 1/2 trial show encouraging outcomes for patients with higher-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) treated with the fully oral regimen of venetoclax and decitabine plus cedazuridine.

Despite the widespread practice of delaying or modifying chemotherapy treatment for patients with COVID-19, the investigators wrote that there are no clear data indicating the benefit of this practice.

Numerous strategies were proposed, including an emphasis on community-based interventions that can reduce psychological stressors associated with clinical settings.

Patients with early-stage hepatocellular carcinoma (HCC) and those with advanced-stage disease exhibited distinct gut microbiota diversity and alterations, with future studies warranted to investigate the mechanisms underlying the interactions between gut microbiota and HCC progression.

The amount of in-network care claims jumped significantly after surprise billing protections took effect; experts say the US is in the midst of the “fourth wave” of the opioid epidemic; the prevalence of long COVID symptoms 30 and 90 days post infection was 43% to 58% lower among adults who were fully vaccinated before infection.

Increased daily step count was linked to reduced risks of overall heart failure (HF) and HF with preserved or reduced ejection fraction.

Researchers suggest an alternative method to align drug prices with clinical benefits for patients with psoriasis.

Medical experts provide their final thoughts regarding key treatment considerations for CLL and SLL.

The panelists provide perspectives on critical aspects of the CLL and SLL treatment landscape.

Eric D. Donnenfeld, MD; underscores the significance of an FDA approved treatment for Demodex blepharitis as well as past alternative treatments.

A new study has found that HLX01 (HanliKang), a rituximab biosimilar, had comparable overall survival and progression-free survival rates to the reference product (Rituxan) in patients with diffuse large B-cell lymphoma (DLBCL).

Patients with chronic obstructive pulmonary disease (COPD) on triple therapy face an increased cardiovascular risk.

Findings reveal an increased risk of psoriatic arthritis (PsA) among female patients with severe skin psoriasis who have nail involvement and require oral systemic therapy for their condition.

No difference in overall survival was observed between patients of different races who had chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and received cancer care or had access to a hematologist/oncologist.

The application is based on results of the phase 3 TROPION-Lung01 trial of datopotamab deruxtecan in nonsquamous non–small cell lung cancer (NSCLC), first presented at the 2023 European Society for Medical Oncology Congress.

Despite socioeconomic and biological differences that contribute to disparities between Black men and White men with prostate cancer, improved access has been shown to reduce the gaps, explained Jun Gong, MD, of Cedars Sinai.

Researchers said these findings confirm that zilebesiran can significantly reduce serum angiotensinogen levels, leading to sustained reductions in blood pressure over a 24-hour period, even 6 months post-treatment, though more research is needed for longer-term use.

Using home insulin pumps when hospitalized was relatively safe compared with hospital-managed pumps and insulin injections among more than 2700 children admitted to a single hospital center.

The retrospective study found patients on Bruton’s tyrosine kinase inhibitors are similar to the general population in the sense that it usually takes at least 2 anti-hypertensive drugs to control blood pressure.

Medicare beneficiaries are beginning to see the first savings from the Inflation Reduction Act; abortion pills prescribed to patients via telehealth and the mail are safe; nearly half of health care workers have witnessed racism or discrimination in their workplace.